glp-1 agonists addiction Substance use disorders (SUDs) may become the next therapeutic target for receptor (GLP-1s). Although the evidence remains preliminary, growing preclinical, observational, and early clinical data suggest these drugs may reduce GLP-1 agonists reduce substance use

However, this approach has also impacted Type 2 diabetes patients access to GLP-1s by requiring some patients to try other diabetes treatments (e.g., blood sugar regulators such as sodium-glucose cotransporter-2 inhibitor Brenzavvy and dipeptidyl peptidase-4 inhibitor Onglyza) before GLP-1 approval

doi:10.3390/nu13072228 [35] Izquierdo-Cassas J, Comas-Baste O, Latorre-Moratalla ML, Lorente-Gascon M, Duelo A, Vidal-Carou MC, Soler-Singla L

Dry or Dehydrated Skin To find out if current issues stem from dry or dehydrated skin, one must look closely at environmental triggers and daily routines

doi: 10.1016/J.INTIMP.2011.10.010 158 LubbadAOriowoMAKhanI

Members: Call or email our team to schedule your peptide therapy appointment